Change of 7.03% for Novocure Limited – Ordinary Shares (NASDAQ:NVCR)’s short interest was recorded. FINRA issued short interest of NVCR’s total 2.96M shares. That’s 7.03% down from 3.18M shares. With Average volume 550,700, NVCR’s former position will take 5 days to restore. Novocure Limited – Ordinary Shares’s short interest float is 4.43%.
The stock decreased 3.82% or $1.37 during the last trading session, reaching $34.54.Currently NovoCure Limited is uptrending after 130.32% change in last December 5, 2017. NVCR has also 824,419 shares volume. The stock outperformed the S&P500 by 114.70%.
NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors.The company has $3.21 billion market cap. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.Last it reported negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.
For more NovoCure Limited (NASDAQ:NVCR) news posted recently go to: Fool.com, Zacks.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Here’s Why NovoCure Popped 157% in 2017 – The Motley Fool” posted on January 09, 2018, “NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates – Zacks.com” on October 25, 2018, “Here’s Why Novocure Ltd. Rose 55% in the First Half of 2018 – Nasdaq” with a publish date: July 14, 2018, “Novocure: Recent Developments And Upcoming Prospects In Mesothelioma – Seeking Alpha” and the last “NovoCure: This Former ROTY Contender Is Far From Finished – Seeking Alpha” with publication date: June 15, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
News Feed From news.google.com